Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023407952> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2023407952 endingPage "404" @default.
- W2023407952 startingPage "401" @default.
- W2023407952 abstract "Choroidal neovascularization (CNV) secondary to pathological myopia (PM) is one of the main causes of severe visual impairment in patients younger than 50 years. In this analysis we want to demonstrate the long-term results of Ranibizumab treating CNV secondary to PM.We retrospectively analysed 15 treatment naive eyes of 13 patients (10 women, 3 men, mean age: 61.5, SD 11.6, range: 41-80) with visual impairment due to CNV secondary to PM, which were treated with ranibizumab. Criteria for re-treatment were reduction of visual acuity and/or activity in OCT or fluorescence angiography.We applied a mean of 3 injections (standard deviation [SD] 2.5, range: 1-8) ranibizumab during a mean period of 39.6 months (SD 5.3, range: 31-52). The spherical equivalent was -12.4 diopters ± 4.1 (range -7.5 to -20.5 diopters). Before the first injection mean visual acuity (logMAR) was 0.69 ± 0.26. After one month visual acuity improved to 0.39 ± 0.23 (p = 0.002), after 3 months to 0.30 ± 0.22 (p = 0.002) and after 6 months up to 0.30 ± 0.22 (p = 0.002). After 12 months visual acuity was 0.30 ± 0.22 (p = 0.001) and after 24 months 0.30 ± SD 0.24 (p = 0.001). 11 patients reached a follow-up of at least 36 months and visual acuity was 0.30 ± 0.13 (p = 0.001).Treating CNV secondary to PM with ranibizumab during a follow-up of 36 months, we found considerable improvement of visual acuity. Compared to treatment of CNV secondary to exudative age-related macular degeneration, CNVs secondary to PM seem to respond faster to ranibizumab treatment and less injections are neccessary to reach stabilization." @default.
- W2023407952 created "2016-06-24" @default.
- W2023407952 creator A5000794110 @default.
- W2023407952 creator A5010602494 @default.
- W2023407952 creator A5045098287 @default.
- W2023407952 date "2013-04-29" @default.
- W2023407952 modified "2023-09-26" @default.
- W2023407952 title "Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia" @default.
- W2023407952 doi "https://doi.org/10.1055/s-0032-1328366" @default.
- W2023407952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23629791" @default.
- W2023407952 hasPublicationYear "2013" @default.
- W2023407952 type Work @default.
- W2023407952 sameAs 2023407952 @default.
- W2023407952 citedByCount "17" @default.
- W2023407952 countsByYear W20234079522013 @default.
- W2023407952 countsByYear W20234079522014 @default.
- W2023407952 countsByYear W20234079522015 @default.
- W2023407952 countsByYear W20234079522016 @default.
- W2023407952 countsByYear W20234079522017 @default.
- W2023407952 countsByYear W20234079522018 @default.
- W2023407952 countsByYear W20234079522019 @default.
- W2023407952 countsByYear W20234079522022 @default.
- W2023407952 crossrefType "journal-article" @default.
- W2023407952 hasAuthorship W2023407952A5000794110 @default.
- W2023407952 hasAuthorship W2023407952A5010602494 @default.
- W2023407952 hasAuthorship W2023407952A5045098287 @default.
- W2023407952 hasConcept C118487528 @default.
- W2023407952 hasConcept C141071460 @default.
- W2023407952 hasConcept C259533 @default.
- W2023407952 hasConcept C2776403814 @default.
- W2023407952 hasConcept C2776694085 @default.
- W2023407952 hasConcept C2777802072 @default.
- W2023407952 hasConcept C2778257484 @default.
- W2023407952 hasConcept C2780248432 @default.
- W2023407952 hasConcept C2781100027 @default.
- W2023407952 hasConcept C2781359195 @default.
- W2023407952 hasConcept C71924100 @default.
- W2023407952 hasConceptScore W2023407952C118487528 @default.
- W2023407952 hasConceptScore W2023407952C141071460 @default.
- W2023407952 hasConceptScore W2023407952C259533 @default.
- W2023407952 hasConceptScore W2023407952C2776403814 @default.
- W2023407952 hasConceptScore W2023407952C2776694085 @default.
- W2023407952 hasConceptScore W2023407952C2777802072 @default.
- W2023407952 hasConceptScore W2023407952C2778257484 @default.
- W2023407952 hasConceptScore W2023407952C2780248432 @default.
- W2023407952 hasConceptScore W2023407952C2781100027 @default.
- W2023407952 hasConceptScore W2023407952C2781359195 @default.
- W2023407952 hasConceptScore W2023407952C71924100 @default.
- W2023407952 hasIssue "04" @default.
- W2023407952 hasLocation W20234079521 @default.
- W2023407952 hasLocation W20234079522 @default.
- W2023407952 hasOpenAccess W2023407952 @default.
- W2023407952 hasPrimaryLocation W20234079521 @default.
- W2023407952 hasRelatedWork W1987334421 @default.
- W2023407952 hasRelatedWork W2011372435 @default.
- W2023407952 hasRelatedWork W2023407952 @default.
- W2023407952 hasRelatedWork W2056892646 @default.
- W2023407952 hasRelatedWork W2074730027 @default.
- W2023407952 hasRelatedWork W2079523484 @default.
- W2023407952 hasRelatedWork W2082606620 @default.
- W2023407952 hasRelatedWork W2099511225 @default.
- W2023407952 hasRelatedWork W2326535627 @default.
- W2023407952 hasRelatedWork W2415042023 @default.
- W2023407952 hasVolume "230" @default.
- W2023407952 isParatext "false" @default.
- W2023407952 isRetracted "false" @default.
- W2023407952 magId "2023407952" @default.
- W2023407952 workType "article" @default.